leadf
logo-loader
viewInnoCan Pharma

Innocan Pharma's cosmetic clinical study indicates 90% wrinkle reduction in volunteers using SHIR Premium CBD Facial Serum

CEO Iris Bincovich said the SHIR Beauty & Science skincare brand combines the benefits of CBD into an innovative formula for fast-acting results

InnoCan Pharma - Innocan Pharma's cosmetic clinical study indicates 90% wrinkle reduction in volunteers using SHIR Premium CBD Facial Serum
The clinical study was conducted by an independent lab at the UPTEC, Science and Technology Park of the University of Porto, in Portugal

InnoCan Pharma Corporation (CSE:INNO) (FRA:IP4) said Friday that it has completed a cosmetic clinical study that showed a dramatic 90% to 95% reduction in facial skin wrinkles after a group of study participants used the company’s SHIR Premium CBD Facial Serum for a period of 28 days. 

The company said a group of 20 volunteers applied SHIR InnoCan Pharma Facial Serum, which has 300 milligrams of cannabidiol, on a sustained basis twice a day for 28 days and saw very positive results. An overwhelmingly high percentage of volunteers saw a more even skin tone and a depigmenting effect after using the product. "The skin was also more moisturized," according to the clinical results.   

"Achieving these amazing results is due to the combination of active ingredients with a specific amount of CBD, which results in tremendous facial skin improvement,” Innocan CEO Iris Bincovich said in a statement.

READ: InnoCan Pharma is taking a true pharmaceutical approach to commercializing cannabinoids

“The SHIR Beauty & Science skincare brand combines the benefits of CBD's most effective ingredients into an innovative formula which is leading to visible fast-acting results. Each ingredient was carefully chosen to provide a synergistic effect, working in harmony with each other.”

Bincovich noted that the “high satisfaction” of the volunteers enrolled at the study pointed to the great potential of the SHIR Beauty & Science skincare line to succeed in a targeted market.

The clinical study was conducted by an independent lab at the UPTEC, Science and Technology Park of the University of Porto, in Portugal. The company said the findings of the clinical study were consistent with the main principles of Portuguese legal requirements.

The Israeli firm markets a line of premium CBD-infused derma cosmetic products distributed throughout the UK and Ireland.

Innocan Israel, a wholly-owned subsidiary of the company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: InnoCan Pharma

Price: 0.28 CAD

CSE:INNO
Market: CSE
Market Cap: $49.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Innocan Pharma bring significant update on Injectable CBD delivery system...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has provided an update on their Injectable CBD delivery system that allows control release. Bincovich telling Proactive some of the recent works done to prove the efficacy of the project...

1 week, 5 days ago

2 min read